Evaluation of Protein Kinase C β and P PAR γ Activity in Diabetic Rats Supplemented with Momordica charantia

Chandru, Swetha; Vishwanath, Prashant; Devegowda, Devananda; Ramasamudra, Suresha Nagaraja; Prashant, Akila; Hathur, Basavanagowdappa

doi:10.7860/jcdr/2016/18161.7653

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies with MC have demonstrated that this plant stimulates the activation of Peroxisome Proliferator-Activated Receptors (PPARs), especially the PPARα and PPARγ subtypes, which facilitate lipid metabolism, reducing blood lipids and the inflammatory process [22] . The decrease of the fat accumulation caused by the plant can consequently result in weight loss effect [23] .…”

Section: Resultsmentioning

confidence: 99%

Effect of Momordica Charantia on The Prevention of Changes in Serum and Hepatic Metabolism of Animals Fed A High Fat Diet

Franco

Porto

2020

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Effect of Momordica Charantia on The Prevention of Changes in Serum and Hepatic Metabolism of Animals Fed A High Fat Diet

Franco

Porto

2020

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

“…Pharmacological studies have established several potential modes of actions through which M. charantia L. could lower high blood glucose and prevent complications. The proposed mechanisms include; improved histological architecture of the islets of Langerhans and beta-cell regeneration [16,21,22], insulin secretagogue [23, 24], enhance peripheral glucose utilization, inhibit glucose-6-phosphatase and fructose biphosphatase glucogenic enzymes [25], increases peroxisome proliferator-activated receptor gamma (PPAR-γ) activity and decreases protein Kinase C (PKC-β) activity in kidneys [26]. Despite the number of preclinical studies performed each year continuing to increase, and our understanding of M. charantia L. mode of action is improving, a recent meta-analysis of five randomized clinical trials confirmed its glucose lowering ability with only very low certainty of evidence [19].…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety ofMomordica charantiaL. in animal models of type 2 diabetes mellitus; A systematic review and meta-analysis

Peter

Nagendrappa

Kaligirwa

et al. 2019

Preprint

View full text Add to dashboard Cite

49Background 50 Momordica charantia L. (Cucurbitaceae) has been used to control hyperglycemia in people with 51 type 2 diabetes mellitus in Asia, South America, and Africa for decades. However, a meta-analysis 52 of clinical trials confirmed very low-quality evidence of its efficacy. To potentially increase the 53 certainty of evidence, we evaluated the effect of M. charantia L. in comparison with vehicle on 54 glycemic control in animal models of type 2 diabetes mellitus. 55 Methods 56Review authors searched in MEDLINE, Web of Science, Scopus, and CINAHL databases without 57 language restriction through April 2019. Two authors independently evaluated full texts, assessed 58 the risk of bias, and extracted data. We analyzed the influence of study design and evidence of 59 publication bias. 60 Results 61The review included 66 studies involving 1861 animals. They had a follow up between 7 and 90 62 days. Majority 29 (43.9%) used Wistar albino rats, and 37 (56.1%) used male animals. Thirty-two 63 (48%) used an aqueous extract of fresh fruits. M. charantia L. reduced fasting plasma glucose 64 (FPG) and glycosylated hemoglobin A1c in comparison to vehicle control (42 studies, 815 65 animals; SMD, -6.86 [95% CI; -7.95, -5.77], 3 studies, 59 animals; SMD; -7.76 [95%CI; -12.50, -66 3.01]) respectively. Magnitude of FPG was large in Wistar albino rat subgroup; SMD; -10.29, 67 [95%CI; -12.55, -8.03]. Publication bias changed FPG to non-significant -2.46 SMD, [95%CI; -68 5.10, 0.17]. We downgraded the evidence to moderate quality due to poor methodological quality, 69 high risk of bias, unexplained heterogeneity, suspected publication bias, and lack of standardized 70 dose. 4 71 Conclusion 72 M. charantia L. lowers elevated plasma glucose level in type 2 diabetes mellitus animal models. 73 Publication bias and poor methodological quality call for future researches to focus on 74 standardizing dose with chemical markers and provide measures to improve preclinical type 2 75 diabetes mellitus studies. 76 Systematic review registration CRD42019119181 77 Keywords 78 Bitter gourd; type 2 diabetes mellitus; efficacy; safety; meta-analysis; preclinical. 79 80 81 82 83 84 85 86 87 88 89 90 91 92 5 93 94 Introduction 95 Type 2 diabetes mellitus (T2DM) is a chronic hyperglycemic condition in response to 96 progressively impaired glucose regulation due to insulin resistance and beta-cell dysfunction [1,2]. 97 The chronicity of hyperglycemia causes microvascular complications in the retina, renal 98 glomerulus and peripheral nerves [3]; and increases the risk of accelerated atherosclerosis and 99 premature death [4]. Other complications include dementia, sexual dysfunction, depression and 100 lower-limb amputations [5-7]. 101 People with T2DM use oral hypoglycemic agents (OHAs) for glycemic control and ameliorating 102 diabetes complications, but the OHAs have in recent years been linked to intolerable side effects 103 and increasing failure rate [8], leaving the majority of people with T2DM using medicinal plants 104 as alternative the...

show abstract

“…The rats displaying fasting plasma glucose levels higher than 250 mg/dl 12 were selected and used in the study.…”

Section: Induction Of Diabetes In Ratsmentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

ABSTRACT:In view of therapeutic values associated with Syzygium cumini and increasing consumer demand for functional foods, a non-conventional alcoholic beverage prepared from the stem of Syzygium cumini was evaluated for its efficacy against streptozotocin-induced diabetes mellitus in male wistar rats. The beverage was observed to be safe for consumption as it did not produce any anomalies in the biochemical markers of liver and kidney of normal rats, rather exerted protective effects on hepatic and renal functions by improving the levels of biochemical indicators. After an oral administration of a daily single of dose of 4ml/kg for a period of 30 days, stem beverage was able to rectify the abnormalities in blood glucose levels, lipid profile and atherogenic index of diabetic rats. The beverage also arrested the deviations in hepatic and renal functions of diabetic rats. Histological studies of pancreas also confirmed the anti-diabetic behaviour of stem beverage. The pharmacological properties of the beverage can be ascribed to the presence of various phenolics and tannins in it. The use of this beverage for the management of diabetes mellitus and associated dyslipidemia is suggested.

show abstract

Evaluation of Protein Kinase C β and P PAR γ Activity in Diabetic Rats Supplemented with Momordica charantia

Cited by 4 publications

References 16 publications

Effect of Momordica Charantia on The Prevention of Changes in Serum and Hepatic Metabolism of Animals Fed A High Fat Diet

Effect of Momordica Charantia on The Prevention of Changes in Serum and Hepatic Metabolism of Animals Fed A High Fat Diet

The efficacy and safety ofMomordica charantiaL. in animal models of type 2 diabetes mellitus; A systematic review and meta-analysis

Untitled

Contact Info

Product

Resources

About